Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Citi
Moodys
Fish and Richardson
Federal Trade Commission
Teva
Healthtrust
US Army
Baxter

Generated: July 18, 2018

DrugPatentWatch Database Preview

RELAFEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Relafen patents expire, and what generic alternatives are available?

Relafen is a drug marketed by Smithkline Beecham and is included in one NDA.

The generic ingredient in RELAFEN is nabumetone. There are twenty drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
Drug patent expirations by year for RELAFEN
Synonyms for RELAFEN
2-Butanone, 4-(6-methoxy-2-naphthalenyl)-
4-(2-Methoxynaphthalen-6-yl)butan-2-one
4-(6-Methoxy-2-naphthalenyl)-2-butanone
4-(6-Methoxy-2-naphthyl)-2-butanone
4-(6-methoxy-2-naphthyl)butan-2-one
4-(6-methoxynaphthalen-2-yl)butan-2-one
4-[6-methoxy-2-naphthyl]-2-butanone
42924-53-8
6-MNA (oral), Nobex
924N538
AB00052392
AB00052392_14
AB00052392_15
AB00052392-13
AC-19025
AC1L1I3P
AC1Q4F4K
AJ-08410
AK-86115
AKOS009529199
AM20040460
Ambap42924-53-8
ANW-46490
API0003472
Arthaxan
AX8142896
Balmox
BC966361
BDBM40128
BIDD:GT0104
BLXXJMDCKKHMKV-UHFFFAOYSA-N
BPBio1_000834
BRD-K65146499-001-04-8
BRL 14777
BRL-14777
BRN 2103472
BSPBio_000758
C-13097
CAS-42924-53-8
CC-32257
CCG-39507
CCRIS 8108
CHEBI:7443
CHEMBL1070
cid_4409
Consolan
CPD000058835
CS-2669
CTK8B4843
D00425
D05CKR
DB00461
DivK1c_000850
Dolsinal
DR000475
DSSTox_CID_25472
DSSTox_GSID_45472
DSSTox_RID_80901
DTXSID4045472
Flambate
FT-0629765
GTPL7245
HMS1570F20
HMS1922G10
HMS2090D13
HMS2093I05
HMS2097F20
HMS2230H12
HMS3259I16
HMS3652M04
HMS502K12
HY-B0559
IDI1_000850
KB-238680
KBio1_000850
KBio2_001966
KBio2_004534
KBio2_007102
KBioGR_000687
KBioSS_001966
KS-1371
Listran
LS-46825
LW0TIW155Z
M727
Mebutan
MFCD00079518
MLS000069541
MLS001076325
MolPort-001-793-710
Nabucox
nabumeton
Nabumetona
nabumetone
Nabumetone (JP17/USP/INN)
Nabumetone (oral)
Nabumetone (oral), Nobex
Nabumetone [USAN:BAN:INN:JAN]
Nabumetone, analytical standard
Nabumetone, British Pharmacopoeia (BP) Reference Standard
Nabumetone, European Pharmacopoeia (EP) Reference Standard
Nabumetone, United States Pharmacopeia (USP) Reference Standard
Nabumetonum
Nabumetonum [INN-Latin]
Nabuser
nabuton
NC00579
NCGC00016853-01
NCGC00016853-02
NCGC00016853-03
NCGC00016853-06
NCGC00095063-01
NCGC00095063-02
NINDS_000850
NNB-001
NNB-004
NNB-005
NSC-758623
NSC758623
Opera_ID_765
OR209175
Pharmakon1600-01503650
Prestwick0_000909
Prestwick1_000909
Prestwick2_000909
Prestwick3_000909
Prodac
Relafen (TN)
Relif
Relifen
Relifex
s4051
SAM002564225
SBI-0051869.P002
SC-77045
SCHEMBL2256
SMR000058835
SPBio_002097
SPBio_002957
Spectrum_001486
SPECTRUM1503650
Spectrum2_001969
Spectrum4_000174
Spectrum5_001286
SR-01000759138
SR-01000759138-2
ST2405403
TC-135235
Tox21_110647
Tox21_110647_1
UNII-LW0TIW155Z
Unimetone
ZB000767
ZINC20221

US Patents and Regulatory Information for RELAFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for RELAFEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Citi
Teva
Moodys
Cerilliant
Covington
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.